Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	42.29	134.55	7.42	13.17	54.59	18.92
Cash & Short-Term Investments	113.26	134.55	7.42	13.17	54.59	18.92
Cash Growth	21.23%	1714.51%	-43.71%	-75.87%	188.52%	424.15%
Accounts Receivable	-	-	-	-	1.06	2.18
Other Receivables	-	0.61	0.14	1.92	3.74	2.21
Receivables	-	0.61	0.14	1.92	4.8	4.39
Inventory	-	-	-	0.02	0.04	0
Prepaid Expenses	1.9	3.71	0.84	1.29	2.37	2.66
Restricted Cash	0.02	0.02	0	0.02	0.05	0.04
Total Current Assets	115.19	138.89	8.4	16.42	61.85	26.01
Property, Plant & Equipment	0.69	1.21	1.97	2.41	2.7	1.61
Goodwill	10.5	10.5	10.5	14.41	14.41	14.41
Other Intangible Assets	-	-	-	-	0.04	1.59
Other Long-Term Assets	0.21	0.13	0.13	0.13	1.23	0.15
Total Assets	126.58	150.73	20.99	33.37	80.21	43.76
Accounts Payable	2.37	0.28	0.45	2.88	3.37	2.57
Accrued Expenses	5.68	5.22	1.76	10.51	14.29	8.86
Current Portion of Long-Term Debt	-	-	-	5.93	-	-
Current Portion of Leases	0.48	0.57	0.54	0.53	0.49	0.43
Current Unearned Revenue	-	-	-	0.09	-	-
Other Current Liabilities	0.73	0.89	1.87	2.17	1.74	3.36
Total Current Liabilities	9.26	6.96	4.62	22.11	19.89	15.23
Long-Term Debt	-	-	-	13.49	32.83	-
Long-Term Leases	0.2	0.35	1.37	1.71	2.02	1.04
Long-Term Deferred Tax Liabilities	0.29	0.27	0.16	0.14	0.11	0.09
Other Long-Term Liabilities	12.26	10.12	7.55	6.83	2.28	2.84
Total Liabilities	22.01	17.7	13.69	44.28	57.13	19.19
Common Stock	0.01	0.01	0	-	0.01	0.08
Additional Paid-In Capital	508.77	503.29	342.44	292.91	285.24	202.28
Retained Earnings	-404.18	-370.26	-335.13	-303.82	-262.17	-177.79
Comprehensive Income & Other	-0.03	-	-	-	-	-
Total Common Equity	104.57	133.03	7.3	-10.92	23.08	24.56
Shareholders' Equity	104.57	133.03	7.3	-10.92	23.08	24.56
Total Liabilities & Equity	126.58	150.73	20.99	33.37	80.21	43.76
Total Debt	0.68	0.92	1.9	21.66	35.34	1.46
Net Cash (Debt)	112.58	133.63	5.51	-8.49	19.25	17.46
Net Cash Growth	22.78%	2324.31%	-	-	10.28%	645.41%
Net Cash Per Share	12.12	17.83	19.85	-216.49	531.87	684.21
Filing Date Shares Outstanding	13.15	10.67	1.03	0.06	0.04	0.56
Total Common Shares Outstanding	10.84	10.47	0.8	0.04	0.04	0.55
Working Capital	105.93	131.93	3.78	-5.7	41.96	10.78
Book Value Per Share	9.65	12.70	9.11	-277.78	589.35	44.33
Tangible Book Value	94.07	122.53	-3.2	-25.32	8.64	8.57
Tangible Book Value Per Share	8.68	11.70	-3.99	-644.47	220.48	15.46
Machinery	-	0.28	0.28	0.34	0.24	0.21
Leasehold Improvements	-	0.9	0.9	0.74	0.74	0.66

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q